Kinase News and Research

RSS

Scientists identify new genetic alterations underlying high-risk subtype of ALL

Scientists have identified new genetic alterations underlying a high-risk subtype of the most common childhood cancer that could be effectively targeted with existing leukemia therapies.

14 Aug 2012

Tofacitinib efficacy suggested for rheumatoid arthritis

The novel oral Janus kinase inhibitor tofacitinib significantly reduces signs and symptoms of rheumatoid arthritis, report two phase III trials published in TheNew England Journal of Medicine.

13 Aug 2012

Verastem second quarter net loss increases to $6.8 million

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today reported financial results for the quarter ended June 30, 2012, and also commented on certain corporate accomplishments and plans.

13 Aug 2012

Manipulating hormone-producing cells in the brain may help control blood sugar levels

Manipulating a group of hormone-producing cells in the brain can control blood sugar levels in the body - a discovery that has dramatic potential for research into weight-loss drugs and diabetes treatment.

10 Aug 2012

Theranostic imaging targets and tracks potent drug therapies to prostate cancer cells

Experimenting with human prostate cancer cells and mice, cancer imaging experts at Johns Hopkins say they have developed a method for finding and killing malignant cells while sparing healthy ones.

9 Aug 2012

Progression-free NSCLC survival boosted by dacomitinib

In patients with non-small-cell lunch cancer, dacomitinib confers a significant progression-free survival benefit over erlotinib across a range of clinical and molecular subgroups, the results of an international study indicate.

8 Aug 2012

Lung cancer patients can be screened for ALK-inhibitor suitability

Anaplastic lymphoma kinase gene status in patients with lung adenocarcinoma can be determined non-invasively using circulating tumor cells, research shows.

8 Aug 2012

Prostate cancer cells can be killed by theranostic imaging without harming healthy cells

Experimenting with human prostate cancer cells and mice, cancer imaging experts at Johns Hopkins say they have developed a method for finding and killing malignant cells while sparing healthy ones.

8 Aug 2012

New class of drugs reduces adverse effects of cellular damage from cancer chemotherapy

Chemotherapy kills tumor cells, but it also wreaks havoc on the rest of the body. A team of researchers led by Igor Roninson of the South Carolina College of Pharmacy just reported the discovery of a new class of drugs that reduces the adverse effects of cellular damage from chemotherapy.

8 Aug 2012

Scripps Florida scientists to identify and develop new therapeutic approaches against cancers

Scientists from the Florida campus of The Scripps Research Institute have been awarded approximately $1.5 million from the National Institutes of Health to identify and develop new therapeutic approaches against a broad spectrum of cancers.

7 Aug 2012

Mutations in Ras gene alone may not cause tumours

Despite a huge amount of research effort, the molecular mechanisms that underlie the transition from a "normal" cell to a cancerous cell are only poorly understood. After the discovery of the first cancer-causing genes or oncogenes and the finding that they are mutated forms of normal cellular genes, it was widely believed that a single mutation was enough to cause cancer.

6 Aug 2012

New role for oncogenic signaling pathway in embryonic stem cell self-renewal

Researchers at Mount Sinai School of Medicine, the University of Manchester, and the MD Anderson Cancer Center have found a new role for an oncogenic signaling pathway in embryonic stem cell (ESC) self-renewal and in reprogramming adult cells into an ESC-state, which will aid in the development of future cancer therapies.

3 Aug 2012

MLK3 protein critical driver of breast cancer cell migration and invasion

By identifying a key protein that tells certain breast cancer cells when and how to move, researchers at Michigan State University hope to better understand the process by which breast cancer spreads, or metastasizes.

2 Aug 2012

Chk1 gene alone is sufficient to kill cancer cells

Researchers at Case Western Reserve University School of Medicine have discovered a mutant form of the gene, Chk1, that when expressed in cancer cells, permanently stopped their proliferation and caused cell death without the addition of any chemotherapeutic drugs.

1 Aug 2012

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

31 Jul 2012

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Pfizer Inc. announced today top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).

31 Jul 2012

New compound effective at blocking damage to the retina in diabetic retinopathy

Researchers at the University of Michigan Kellogg Eye Center have identified a compound that could interrupt the chain of events that cause damage to the retina in diabetic retinopathy. The finding is significant because it could lead to a novel therapy that targets two mechanisms at the root of the disease: inflammation and the weakening of the blood barrier that protects the retina.

30 Jul 2012

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

ARIAD Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).

28 Jul 2012

Potential biomarker to predict lung cancer patients' response to chemotherapy

Patients with the most common type of lung cancer are notoriously insensitive to chemotherapy drugs, including cisplatin. New findings related to the cellular pathways that regulate responses to cisplatin have now been published by Cell Press on July 26th in the journal Cell Reports.

27 Jul 2012

Fusion of FGFR and TACC gene leads to glioblastoma

Researchers at Columbia University Medical Center (CUMC) have discovered that some cases of glioblastoma, the most common and aggressive form of primary brain cancer, are caused by the fusion of two adjacent genes.

26 Jul 2012

Kinase News and Research

Scientists identify new genetic alterations underlying high-risk subtype of ALL

Tofacitinib efficacy suggested for rheumatoid arthritis

Verastem second quarter net loss increases to $6.8 million

Manipulating hormone-producing cells in the brain may help control blood sugar levels

Theranostic imaging targets and tracks potent drug therapies to prostate cancer cells

Progression-free NSCLC survival boosted by dacomitinib

Lung cancer patients can be screened for ALK-inhibitor suitability

Prostate cancer cells can be killed by theranostic imaging without harming healthy cells

New class of drugs reduces adverse effects of cellular damage from cancer chemotherapy

Scripps Florida scientists to identify and develop new therapeutic approaches against cancers

Mutations in Ras gene alone may not cause tumours

New role for oncogenic signaling pathway in embryonic stem cell self-renewal

MLK3 protein critical driver of breast cancer cell migration and invasion

Chk1 gene alone is sufficient to kill cancer cells

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

New compound effective at blocking damage to the retina in diabetic retinopathy

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

Potential biomarker to predict lung cancer patients' response to chemotherapy

Fusion of FGFR and TACC gene leads to glioblastoma

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News